The ability of airway epithelial cells to produce transforming growth factor-(3 (TGF-i) may be an important mechanism for the control of growth, differentiation, and repair of the airway epithelium. To determine whether airway epithelial cells are capable of producing TGF-fi, we examined primary cultures of bovine bronchial epithelial cells. Using a bioassay, TGF-ft activity was detected readily in media conditioned by bovine bronchial epithelial cells. Neutralizing antisera to TGF-ft1 and TGF-ft2 were used to demonstrate that the majority ofthe activity was of the TGF-,82 isoform. Interestingly, some of the TGF-,B activity was present in the conditioned media as "active" TGF-fl, not requiring acid activation. The production of TGF-(3 was variable, depending on cell density and the presence of retinoic acid. The presence of endogenously produced active TGF-,6 in the culture media was shown to modulate the behavior of the cell cultures as evidenced by the effects of TGF-flneutralizing antisera on cell size and fibronectin production.
Introduction
A number of growth factors appear to be important for the growth and differentiation of airway epithelial cells (1) (2) (3) .
Transforming growth factor-: (TGF-f3),' often described by a transformation assay (4) , has a broad range of effects on growth and differentiation of many cell types and has the striking effect of causing terminal squamous differentiation of tracheobronchial cells in vitro (5, 6) . Concentrations ofTGF-,3 as low as 1 pM inhibit the growth of primary cultures of tracheal epithelial cells with the cells accumulating in the GO-GI phases of the cell cycle and tending to become squamous with TGF-fl( 1-3) have been described in mammals and they appear to play important roles in the developing lung as they have been shown to colocalize with matrix proteins in the developing lung of the mouse embryo (7, 8) . TGF-fl is also likely to play important roles in the repair of injured epithelium since it is known to influence wound healing in several systems (9) and has marked effects on the regulation of extracellular matrix proteins ( 10, 11 ) .
TGF-fl is present in the epithelial lining fluid ofthe normal human lower respiratory tract at a concentration estimated between 200 and 300 pM ( 12) . Since this value is 15-fold greater than the concentration of TGF-f, in plasma, the majority of TGF-,B present in the epithelial lining fluid may be produced by cells present in the respiratory tract. Several potential sources of TGF-,B exist. Alveolar macrophages are one potential source of TGF-3 in the lower respiratory tract as they are known to constitutively express the gene ( 13, 14) . In a recent study of the normal adult mouse lung, mRNA transcripts for TGF-fl 1, -(2, and -03 were found in smooth muscle cells and fibroblasts ( 15 ) . One immunohistochemistry study of lung tissue from subjects with advanced pulmonary fibrosis demonstrated increased localization of TGF-f3 in bronchiolar epithelium ( 16 ) . Thus, epithelial cells may be a source of TGF-fl in some conditions. Other normal mammalian cell types and tissues have been shown to produce TGF-fl in culture, including keratinocytes ( 17) . The (23) . 10 Al of 1 N HCI was added to I ml of neutral CM to reduce the pH from 7.2 (neutral CM) to 1.6-1.8 (acidified CM). After 15 min at 4°C, the pH was neutralized with 10 Al of I N NaOH.
Assayfor TGF-fl activity. TGF-fl activity was determined by measuring the inhibition of [3Hjthymidine incorporation by (ATCC) cells (24) (25) (26) (27) [3H]Thymidine (0.5 MCi/ml) was added for an additional 2 h before harvesting for scintillation counting. The TGF-j92 dilutions and test media were assayed in triplicate.
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Sacco, Romberger, Rizzino, Beckmann, Rennard, and Spurzem 0 with PBS-Tween (0.08% Tween). The samples were incubated overnight at 40C in a humidified chamber with 1:400 dilution of rabbit anti-bovine fibronectin serum. The following day the samples were transferred to the flat-bottom plates, which had been previously washed three times with PBS-Tween. After a 30-min incubation, the flat-bottom plates were again washed three times with PBS-Tween and 200 ,l/well of a 1:1,000 dilution of goat anti-rabbit IgG conjugated with horseradish peroxidase (ICN ImmunoBiologicals, Lisle, IL) were added. After 90 min the plates were again washed three times with PBS-Tween followed by the addition of200 ul/well ofo-phenylenediamine substrate ( 10 mg dissolved in 1 ml methanol/ 100 ml H20) with 10 Ml of 30% of H202. The enzymatic reaction was stopped with 28 ,Ml/well of 4 N H2SO4. The absorbance was then measured at 492 nm using an ELISA reader (model 2550 EIA Reader; Bio-Rad Laborato- 
Results
Release of TGF-13-like activity by bronchial epithelial cells. When the bronchial epithelial cells were cultured at middensity in serum-free conditions, TGF-f3-like activity was detected in CM (Fig. 2 A) . Thus, active TGF-f3 appears to be produced by the bronchial epithelial cell cultures. To quantify both the active and inactive latent TGF-f present in the CM, total TGF-f3 was assayed by subjecting aliquots ofthe same CM to the acidactivation procedure (23) . Approximately 5-10-fold more TGF-j3 activity was detected (Fig. 2 B) , demonstrating that the majority ofTGF-f produced was in the latent form. The quantity of TGF-f3 activity in the CM was roughly similar to that reported for another cell system, bovine aortic endothelial cells (30) . cells/dish). Every 24 h three dishes were trypsinized for cell counts with a Coulter counter (ZM; Coulter Electronics) and the medium ( 1.5 ml/dish) changed. The harvested CM was processed for TGF-# bioassay as specified in Methods. The total TGF-f3-like activity present in the acidified CM is expressed as pg of TGF-3 produced every 24 h and normalized for 1 X 106 bronchial epithelial cells. The differences in peak production of TGF-3 between the three conditions were significant at P < 0.05, analysis of variance. distinguish between TGF-f31 and TGF-32 revealed that a turkey antiserum to TGF-3l had negligible effect in neutralizing the TGF-13 activity in both neutral and acidified CM (Table I) . In contrast, a rabbit antibody to TGF-,32 was effective in neutralizing the TGF-f3 activity present in bronchial epithelial cell CM. In the neutral CM, all of the TGF-0-like activity was neutralized by the anti-TGF-32 antibody. In the acidified CM, the anti-TGF-,B2 antibody was effective in neutralizing the majority, but not all of the activity measurable in the CCL-64 bioassay. A turkey anti-TGF-,32 antiserum gave similar results (data not shown). The residual growth inhibitory activity in acidified CM is unlikely to be entirely due to active TGF-#31, since the rabbit TGF-#13-2 neutralizing antibody showed no better performance in neutralizing the TGF-f3-like activity of the acidified CM. To confirm the activity ofthe antisera used to evaluate the bronchial epithelial cell CM in our assay systems, the same serial dilutions of the antibodies were tested against purified TGF-1 I and -132 at 250 pg/ml. The neutralizing antisera were effective as expected against the relevant TGF-,3 type. Thus, the majority of TGF-,B activity produced by bronchial epithelial cells in vitro appears to be TGF-i32.
Effect ofcelldensity on release of TGF-0 by bronchial epithelial cells. It was noted above (Fig. 2) that production ofTGF-, decreases at or after the cells reach confluence (usually from day 4 to day 5). Since TGF-,B is thought to function as an autocrine mediator ofepithelial differentiation and its production can be density dependent ( 31 ), we evaluated the effect of cell density on TGF-,B production by bronchial epithelial cells. Primary cultures of bronchial epithelial cells were cultured at three different densities as described in Methods. We determined that cells cultured at low density produced more TGF-j3 on a per cell basis than cells that were plated at higher densities (Fig. 3) .
Effect of retinoic acid on production of TGF-fl. Since our usual growth media for bronchial epithelial cells (LHC-9/ RPMI) contains retinoic acid, and retinoic acid has been shown to induce the expression of TGF-132 by keratinocytes (32) and during early mammalian development (25), we investigated its role in the production of TGF-,B by bronchial epithelial cells. The presence of retinoic acid (0.33 nM) increased the total TGF-13 produced by the cells (Fig. 4) . The percent increase in TGF-,B production caused by retinoic acid ranged from 27% early in the time course to 57% later in the time course, but the differences in TGF-(3 production narrowed by day 6 of the cultures. In most cases, this occurred when TGF-# production began to decrease as seen in Fig. 2 . The differences in TGF-O production were significant at P < 0.01 (paired t test). The effect of retinoic acid on TGF-13 production did not appear to be directly due to an alteration in cell density, as the results were normalized for cell number. Furthermore, retinoic acid at the concentration used did not appear to alter cell proliferation as determined by direct measurements of cell number. In addition, retinoic acid does not appear to influence the TGF-,B isoform produced by the cultured bronchial epithelial cells. Using the neutralizing antibodies specific for TGF-131 and TGF-132 as described above, we found that in the absence ofretinoic acid the TGF-fl-like activity present in the neutral bronchial epithelial cell CM still appears to be TGF-,B2 (data not shown). Evaluation ofthe role ofTGF-$ in squamous differentiation of bronchial epithelial cells. TGF-,B induces tracheobronchial epithelial cell to undergo squamous differentiation (6) and this effect is particularly evident on low density cell cultures. Therefore, we tested the effect of native bronchial epithelial cell CM on one measure of squamous differentiation, cell surface area (33) . TGF-fl-neutralizing antibodies added to the culture medium attenuated the frequency ofbronchial epithelial cells cultured at low density to acquire a squamous morphology (Fig.  5) . The anti-TGF-,B1 and -,B2 antibody decreased the mean planar area per cell from 1,322±160 ,um2 (control cells) to 847±78 (P < 0.05). Whereas the control nonimmune rabbit IgG preparation at the same concentration (32 ,ug/ml) showed no effect on the mean cell surface. Bronchial The bronchial epithelial cells were plated at 24 X 103 cells/chamber (equal to low density cells in 60-mm dishes) in LHC-9/RPMI in four-chamber, tissue culture glass slides (Lab-Tek, Nunc, Naperville, IL) that were coated with collagen. The following day the medium was replaced with fresh medium, with or without anti-TGF-,Bl and two antibodies and bronchial epithelial cell CM. Each neutralizing antibody concentration was high enough to neutralize 1 ng TGF-fl/ ml. The bronchial epithelial cell CM was neutral CM used at a concentration to achieve 250 pg/ml of TGF-,B. This preparation of bronchial epithelial cell CM was split after dilution and one half was incubated with rabbit anti-TGF-fl1
and-fl2-neutralizing antibody at a concentration able to neutralize 1.25 ng of TGF-,B/ml. As a positive control, 250 pg/ml of purified TGF-(32 was used. As a negative control, an equivalent amount of a nonimmune rabbit IgG was used. Every 24 h the medium was replaced with fresh medium with the same condition for each chamber. which contains active TGF-fl, further increased the cell surface area to 2,655±358 (P < 0.01; compared with control). The same preparation ofbronchial epithelial cell CM, preincubated with the TGF-lI and -(32-neutralizing antibody lost its ability to induce squamous differentiation, yielding a mean surface area per cell of 931±63. Purified TGF-,B2 used at the same concentration as the active TGF-f3 in the CM, 250 pg/ml, had a similar effect. The mean surface area was increased to 3,004±453 (P < 0.01; compared with control).
Evaluation ofthe role of TGF-,B in the growth ofbronchial epithelial cells. TGF-fls inhibit proliferation of almost all nonneoplastic epithelial cells in culture (34, 35 ). Therefore, we tested the growth effect of neutral CM from confluent bronchial epithelial cells (Fig. 6) . Neutral bronchial epithelial cell CM had an inhibitory effect on the growth ofbronchial epithelial cells (P < 0.001 compared with control on days 5, 7, and 9). The growth inhibition shown by the TGF-f3-like activity present in the neutral CM was comparable to the degree of inhibition produced by a theoretically equal amount of purified TGF-(3 (250 pg/ml). Preincubation of the neutral CM with the TGF-#31 and -(32-neutralizing antibody blocked the growth inhibitory effects, confirming that TGF-( in the neutral CM was responsible for the growth inhibition seen (Fig. 6 ).
Evaluation ofthe role ofTGF-f3 on production offibronectin by bronchial epithelial cells. TGF-# is a well-known inducer for the expression of the fibronectin gene (36 (Fig. 7) . The differences in fibronectin production were significant at P < 0.01 (paired t test).
Discussion
Our studies demonstrate that primary cultures ofbovine bronchial epithelial cells are capable of producing both active and inactive TGF-(3 and that the majority of TGF-(3 produced is TGF-#2. The results also suggest that TGF-f3 may contribute to the modulation of squamous differentiation and the production of fibronectin.
The amount of active and inactive TGF-fl produced was affected primarily by the time in culture, the plating cell density, and the presence of retinoic acid in the medium. Primary bronchial epithelial cells exhibit a very low basal production of latent TGF-(3 at the beginning of the culture, which progressively increased until cell confluency. Our data also suggest that cell density regulates the production of active TGF-f3 by primary cultures of bronchial epithelial cells. This is of further (38) . Furthermore, plasmin inhibitors were shown to block the activation of inactive TGF-,B described in coculture of endothelial cells and pericytes in serum-free conditions (39) . It is also known that TGF-O induces plasminogen activator inhibitor type 1 in bronchial epithelial cells (40) .
Thus, the induction of protease inhibitors as the cells accumulate more TGF-f may be an explanation for the decrease in the percent of TGF-f that is active (Fig. 2) . It is reasonable to speculate that bronchial epithelial cells secrete proteases or have cell proteases that activate TGF-fl and can also produce inhibitors of proteases. Currently, we have no direct evidence for proteolysis in activating TGF-j3 in our system. Thus far, the addition of the plasmin inhibitors e-amino-n-caproic acid and aprotinin to bronchial epithelial cell cultures has had no effect on the production of active TGF-fl (data not shown).
The antibodies used in the present study suggest that most of the TGF-# activity released by the bovine bronchial epithelial cells is TGF-f2 and not TGF-f31. These results do not exclude, however, the production of other isoforms of TGF-fl by these cells. The significance of bronchial epithelial cell production of TGF-32 in excess of other TGF-,B isoforms (like TGF- (1) is unclear. At least five different isoforms of TGF-f have been described (41 ) with an extraordinary conservation of sequence in organisms as disparate as mammalians and amphibians. This evolutionary conservation underlines the universality of TGF-f action, but the reasons for so many isoforms are puzzling. TGF-O 1 and -(32, the two most studied isoforms, are nearly identical in their biological activity, although there is evidence for differences in binding to different TGF-,3 receptors (42, 43) .
The production of active TGF-f3 by bronchial epithelial cells at sites of injury may be an important event in healing processes in vivo. TGF-f3 is a powerful chemoattractant for neutrophils, mononuclear cells, and fibroblasts (44, 45) . In another study, application of TGF-f31 to the chicken chorioallantoic membrane resulted in early accumulation of endothelial cells, fibroblasts, and epithelial cells, despite the observation that all the cell types showed growth inhibition to TGF-# (46) . An important role for TGF-,3 in pulmonary inflammation was also shown in a model of bleomycin-induced lung injury (47) . In addition, modulation offibronectin production by TGF-p may be an important modifier of cell accumulation and healing at sites of injury. In this regard, fibronectin is a chemoattractant for both fibroblasts and bronchial epithelial cells (48) . Thus, increases in local fibronectin production induced by TGF-3 might amplify the effect of active TGF-,B in recruiting more cells at the site of mucosal injury.
In conclusion, cultures ofprimary bronchial epithelial cells produce TGF-,B and release some in an active form. This potent cytokine can then function in an autocrine or paracrine manner to modulate epithelial cell behavior. Additional studies are needed to identify all TGF-f targets and to investigate the mechanisms by which TGF-f is activated and how the activation mechanisms themselves are controlled.
